Astellas
Last updated Jul 11, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
87%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- ADC
- Bladder Cancer
Highest priority development: FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Regulatory precedent
Why this matters: sets a approval precedent in the same sub-indication (bladder cancer) as Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 87%
Active Signals
2
Investigate Priority
1
Opportunity Score
50
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- InvestigateJul 11, 2026Score 28FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Oncology · Bladder Cancer
- MonitorJul 15, 2026Score 22FDA grants priority review for PADCEV supplemental application
Oncology · ADC
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancerHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinomaHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Withdrawn | Cancer Accelerated ApprovalsModerate Confidence · 84%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — PADCEV (SUPPL)High Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 28FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Oncology · Bladder Cancer
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Astellas right now?
- Which regulatory precedents should Astellas monitor in Oncology and ADC?
- Which pipeline programs should Astellas prioritize for competitive review?
- What signals require immediate investigation for Astellas?
- Summarize the strategic implications of recent developments for Astellas.
- Where is the greatest uncertainty in Astellas's competitive positioning?